Penem Antibiotics (Carbapenems) are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections.

Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are typically unaffected by emerging antibiotic resistance, even to other beta-lactams.

The global Penem Antibiotics market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Penem Antibiotics Industry Forecast” looks at past sales and reviews total world Penem Antibiotics sales in 2022, providing a comprehensive analysis by region and market sector of projected Penem Antibiotics sales for 2023 through 2029.

This Insight Report provides a comprehensive analysis of the global Penem Antibiotics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyses the strategies of leading global companies with a focus on Penem Antibiotics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Penem Antibiotics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Penem Antibiotics and breaks down the forecast by:

• Type
• Application
• Geography
• Market Size to highlight emerging pockets of opportunity.

With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Penem Antibiotics.

United States market for Penem Antibiotics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Penem Antibiotics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Penem Antibiotics is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Penem Antibiotics players cover:

• Sumitomo Pharma
• Merck Sharp & Dohme
• Savior Lifetec
• ACS Dobfar
• Pfizer

This report presents a comprehensive overview, market shares, and growth opportunities of Penem Antibiotics market by:

• Product type
• Application
• Key players
• Key regions and countries

Segmentation by Type:

• Meropenem
• Imipenem
• Biapenem
• Ertapenem
• Others

Segmentation by Application:

• Hospital
• Clinic
• Others

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration:

• Sumitomo Pharma
• Merck Sharp & Dohme
• Savior Lifetec
• ACS Dobfar
• Pfizer
• Eugia Pharma
• Venus Remedies
• Sun Pharmaceutical
• JW Pharmaceutical
• Aurobindo Pharma
• Daiichi Sankyo
• Maruho
• Taiwan Biotech
• Shenzhen Haibin Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• Cspc Holdings
• Zhuhai United Laboratories
• Haikou Pharmaceutical Factory
• Chia Tai Tianqing Pharmaceuticals
• Jiangsu Simcere Pharmaceutical